

# 5.21.076

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	March 18, 2016
<b>Subject:</b>	Halaven	<b>Page:</b>	1 of 5

---

**Last Review Date:** March 6, 2026

---

## Halaven

### Description

#### Halaven (eribulin mesylate)

#### Background

Halaven (eribulin mesylate) is a non-taxane microtubule inhibitor used for the treatment of patients with metastatic breast cancer or unresectable or metastatic liposarcoma. Halaven inhibits the growth phase of the microtubule by inhibiting formation of mitotic spindles causing mitotic blockage and arresting the cell cycle at the G<sub>2</sub>/M phase, which ultimately leads to apoptotic cell death. In addition, Halaven treatment of human breast cancer cells caused changes in morphology and gene expression as well as decreased migration and invasiveness in vitro (1).

#### Regulatory Status

FDA-approved indications: Halaven is a microtubule inhibitor indicated for the treatment of patients with: (1)

1. Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
2. Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

Halaven label includes warnings citing the risk for neutropenia, peripheral neuropathy, embryo-fetal toxicity, and QT prolongation (1).

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	March 18, 2016
<b>Subject:</b>	Halaven	<b>Page:</b>	2 of 5

---

ECG monitoring is recommended if therapy is initiated in patients with congestive heart failure, bradyarrhythmias, taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics, and with electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating Halaven and monitor these electrolytes periodically during therapy. Avoid Halaven in patients with congenital long QT syndrome (1).

Assess for peripheral neuropathy and obtain complete blood cell counts prior to each dose. Do not administer Halaven if ANC < 1,000/mm<sup>3</sup>, platelets < 75,000/mm<sup>3</sup> and/or in the presence of grade 3 or 4 non-hematological toxicities (1).

Halaven can cause fetal harm when administered to a pregnant woman. Advise female patients of reproductive potential to use effective contraception during treatment with Halaven and for at least 2 weeks following the final dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with Halaven and for 3.5 months following the final dose (1).

Halaven was not studied in patients with severe hepatic impairment (Child-Pugh C) (1).

The safety and effectiveness of Halaven in patients less than 18 years of age have not been established (1).

## Related policies

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Halaven may be considered **medically necessary** if the conditions indicated below are met.

Halaven may be considered **investigational** for all other indications.

## Prior-Approval Requirements

**Age** 18 years of age or older

### Diagnoses

Patient must have **ONE** of the following:

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	March 18, 2016
<b>Subject:</b>	Halaven	<b>Page:</b>	3 of 5

---

1. Metastatic breast cancer
  - a. Previously treated with at least two chemotherapy regimens including an anthracycline and taxane
2. Unresectable or metastatic liposarcoma
  - a. Previously treated with an anthracycline-containing regimen

**AND NONE** of the following:

1. Severe hepatic impairment (Child-Pugh C)

## **Prior – Approval *Renewal* Requirements**

**Age** 18 years of age or older

### **Diagnoses**

Patient must have **ONE** of the following:

1. Metastatic breast cancer
2. Unresectable or metastatic liposarcoma

**AND NONE** of the following:

1. Severe hepatic impairment (Child-Pugh C)
2. Disease progression or unacceptable toxicity

### [Policy Guidelines](#)

## **Pre – PA Allowance**

None

## **Prior - Approval Limits**

**Duration** 12 months

## **Prior – Approval *Renewal* Limits**

Same as above

### [Rationale](#)

## **Summary**

# 5.21.076

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	March 18, 2016
<b>Subject:</b>	Halaven	<b>Page:</b>	4 of 5

---

Halaven (eribulin mesylate) is a non-taxane microtubule inhibitor used for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease; and for the treatment of unresectable or metastatic liposarcoma in patients who have received a prior anthracycline-containing regimen. Halaven label includes warnings for the risk for neutropenia, peripheral neuropathy, embryo-fetal toxicity, and QT prolongation. Halaven was not studied in patients with severe hepatic impairment. Halaven can cause fetal harm when administered to a pregnant woman. The safety and effectiveness of Halaven in patients less than 18 years of age have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Halaven while maintaining optimal therapeutic outcomes.

## References

1. Halaven [package insert]. Woodcliff Lake, NJ; Eisai Inc.; September 2022.
2. NCCN Drugs & Biologics Compendium<sup>®</sup> Eribulin 2026. National Comprehensive Cancer Network, Inc. Accessed on January 9, 2026.

## Policy History

Date	Action
March 2016	Addition to PA
June 2016	Annual review
June 2017	Annual editorial review and reference update Addition of age limit to renewal criteria
June 2018	Annual editorial review
June 2019	Annual review and reference update
December 2019	Annual review
March 2020	Annual review
June 2020	Annual review
September 2020	Annual review
June 2021	Annual editorial review and reference update
June 2022	Annual review and reference update
June 2023	Annual review and reference updated. Changed policy number to 5.21.076
June 2024	Annual review and reference update
March 2025	Annual review and reference update
March 2026	Annual review and reference update

## Keywords

# 5.21.076

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	April 1, 2026
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	March 18, 2016
<b>Subject:</b>	Halaven	<b>Page:</b>	5 of 5

---

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 6, 2026 and is effective on April 1, 2026.**